FDA approves technology used to breed PRRS-resistant pigs

The US Food and Drug Administration (FDA) announced it has granted approval to PIC for the gene edit used in its PRRS-resistant pig, determining that the technology is safe and effective. This is a landmark approval, as PIC becomes among the first companies to gain approval for gene editing in commercial livestock in the US. However, PIC noted that FDA approval does not automatically trigger commercialization in the US.

“We have spent years conducting extensive research, validating our findings and working with the FDA to gain approval,” said Matt Culbertson, PIC’s Chief Operating Officer. “Today marks a major milestone for consumers, farmers and the entire pork industry who have desperately hoped for a solution to PRRS.”

The FDA-approved gene edit will be used to breed PIC’s PRRS-resistant pigs, which are resistant to Porcine Reproductive and Respiratory Syndrome (PRRS), one of the most devastating, global swine diseases.

“Addressing PRRS can allow us to improve animal welfare and reduce the environmental impact of raising pigs,” said Banks Baker, Global Director of Product Sustainability. “Recent research indicates that PRRS increases the need for antibiotics by more than 200%. Plus, a recent ISO-conformant lifecycle assessment found that eliminating PRRS could reduce greenhouse gas emissions by 5% in the U.S.”